Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 2c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.72), $0.02 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $41.83 million versus the consensus estimate of $36.04 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Rigetti Computing (RGTI) call put ratio 10.4 calls to 1 put with a focus on June 26 weekly 25 calls as share price up 2.8%